JOHN J ORLOFF

CIK 1643941 · EVP, Research & Development · last filed 2026-06-17

JOHN J ORLOFF is an EVP, Research & Development who has filed 22 SEC Form 4 insider transactions across 3 companies since 2015. The most recent filing, for ZBIO, was dated Jun 17, 2026. 14 SEC filings were submitted jointly with ALEXION PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

3

Total Filings

22

Lifetime Open-Market Net

$0

Filer Profile

Reported Address

C/O BAXALTA INCORPORATED
1200 LAKESIDE DRIVE
BANNOCKBURN, IL 60015

Related Filers

ALEXION PHARMACEUTICALS, INC. — 14 joint filings, latest 2021-07-23

QLT INC/BC — 4 joint filings, latest 2018-08-13

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
ZBIO	Director	—	$31.12	—	$0	3	2026-06-17
NOVELION THERAPEUTICS INC. (NVLN) Delisted	See Remarks	—	—	—	$0	3	2018-08-13
Baxalta Inc (BXLT) Delisted	EVP and President, R&D	96,009	—	—	$0	2	2016-03-07

Recent Filings

22 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-06-17	ZBIO	Grant (A)	—	$0	EDGAR
2025-06-12	ZBIO	Grant (A)	—	$0	EDGAR
2024-09-16	ZBIO	Grant (A)	—	$0	EDGAR
2021-07-23	—	Disp (D)	−146,511	$0
2021-07-16	—	Grant (A)	+60,144	$0
2021-06-09	—	Tax (F)	−1,957	-$346.4K
2021-03-02	—	Grant (A)	+24,473	$0
2020-12-18	—	Mixed	+19,322	-$3.38M
2020-06-09	—	Tax (F)	−2,784	-$319.1K
2020-03-03	—	Mixed	+9,522	-$122.8K

Showing 1–10 of 22

Page 1 of 3 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.